Completed PHASE2 INTERVENTIONAL NCT00086463

Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

A Safety and Pilot Efficacy Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With PAH

Sponsor: Actelion

Conditions Ayerza Syndrome Pulmonary Arterial Hypertension Pulmonary Hypertension

Updated 5 times since 2017 Last updated: Mar 31, 2011 Started: Jun 30, 2004 Primary completion: Jan 31, 2006 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ayerza Syndrome and Pulmonary Arterial Hypertension and is currently completed. Actelion leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Actelion

Data source: Actelion

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Birmingham, United States , Chicago, United States , Denver, United States , Durham, United States , Houston, United States , La Jolla, United States , Nashville, United States , New York, United States and 6 more locations